Dr. Shakti Ramkissoon is board certified in anatomic pathology and neuropathology with expertise in adult and pediatric brain tumors. He obtained his MD/PhD from Rutgers -- New Jersey Medical School, concentrating on cancer stem cell biology. Dr. Ramkissoon then completed an anatomic pathology residency and neuropathology fellowship training at Brigham and Women's Hospital (BWH), Boston, Mass. After completing his clinical training, Dr. Ramkissoon joined the neuropathology faculty at BWH and began his post-doctoral fellowship focused on integrating preclinical data with histologic and molecular findings to inform and design clinical trials for adult and pediatric brain tumors. During his fellowship he completed a master's in biomedical informatics within the Center for Biomedical Informatics at Harvard Medical School.
- Jun 07, 2025 Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage
- May 31, 2025 Unveiling the differences in tumor immune microenvironment between KRAS-wildtype and KRAS-mutant pancreatic ductal adenocarcinoma
- Nov 26, 2024 Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1
- Nov 23, 2024 Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers
- Nov 23, 2024 Analytical validation of OmniSeq® INSIGHT whole transcriptome sequencing assay to facilitate precision oncology through tumoronly testing in solid tumors
- Nov 23, 2024 Analytical validation of OmniSeq® INSIGHT whole exome sequencing assay to facilitate precision oncology through tumor only testing in solid tumors
- Oct 30, 2024 Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer - a case series of divergent results from a large reference laboratory
- Oct 29, 2024 A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
- Apr 29, 2024 Immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer
- Apr 07, 2024 Analytical Performance of Contrived Samples for Validation of Liquid Biopsy Assays
- Apr 07, 2024 Pre-analytical characterization of cell-free DNA to enable liquid biopsy for solid tumors
- Apr 07, 2024 Landscape of HIF-1-alpha expression across 24,186 solid tumors using comprehensive immune profiling
- Apr 07, 2024 Landscape of TIGIT and PD-L1 co-expression in solid tumors
- Apr 07, 2024 Validation of an Automated, Scalable Comprehensive Genomic Profiling Assay for Hematologic Malignancies
- Mar 19, 2024 The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
- Feb 12, 2024 Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
- Jan 10, 2024 Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy
- Dec 11, 2023 Findings of clinically significant variants (Tier IA) with comprehensive genomic profiling in a breast cancer patient cohort
- Dec 11, 2023 Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer
- Nov 17, 2023 Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response
- Nov 17, 2023 Genomic stability of prostate cancers with homologous recombination gene alterations
- Nov 17, 2023 Detecting Molecular Residual Disease Through Integrated Tumor Tissue, Germline, and Plasma Whole Genome Sequencing Analyses
- Nov 17, 2023 Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy
- Nov 17, 2023 Performance Assessment of the Labcorp® Plasma Complete™ Test for Comprehensive Genomic Profiling of Solid Tumors Through Liquid Biopsy
- Nov 17, 2023 Laboratory Automation of PGDx elio™ Tissue Complete on the Biomek NGeniuS System Enables Accurate and Reproducible Comprehensive Genomic Profiling
- Nov 17, 2023 Real-World Evidence Demonstrating the Clinical Performance and Utility of the Labcorp® Plasma Focus™ Liquid Biopsy Test
- Nov 17, 2023 Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making
- Nov 17, 2023 LAG-3 expression by RNA next-generation sequencing: Comparison with LAG-3 immunohistochemistry in melanoma
- Nov 17, 2023 A Consensus-Based Machine Learning Framework to Determine Genetically Inferred Ancestry (GIA) from Comprehensive Genomic Profiling (CGP) Sequencing Results
- Nov 14, 2023 Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
- Nov 04, 2023 Distinct immunotherapy immune response phenotypes in non-small cell lung cancer present with unique genomic alteration profiles
- Nov 03, 2023 Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers
- Nov 03, 2023 Characterization of gene expression signatures of tumor immunogenicity and cellular proliferation from murine cancer models grown in vitro and in vivo
- Nov 03, 2023 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
- Nov 03, 2023 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)
- Nov 03, 2023 Immune microenvironment of primary versus metastatic melanoma of the brain
- Nov 03, 2023 Metastatic triple negative breast cancer has distinct tumor immune landscape
- Nov 01, 2023 Comprehensive Genomic and Immune Profiling of Early-Onset Colorectal Cancer
- Sep 29, 2023 PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
- Aug 14, 2023 Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies
- Jun 01, 2023 Evolving landscape of HER2-low breast cancer: New diagnosis and treatment paradigm shift
- May 08, 2023 RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers
- Apr 20, 2023 Development of a mutation profiling NGS assay to facilitate clinical decisions in hematologic malignancies
- Apr 20, 2023 Genomic landscape of patients with non-small cell lung cancer
- Apr 14, 2023 Validation of the Labcorp Plasma Focus test to facilitate precision oncology through cell-free DNA genomic profiling of solid tumors
- May 18, 2022 Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer
- Feb 14, 2024 Cancer testis antigen burden (CTAB): a novel biomarker of tumor‑associated antigens in lung cancer